Gameto, which is a biotechnology company, has been awarded funding of $10 million from ARPA-H’s Sprint for Women’s Health, and this funding will be utilized for the research of the Menopause Program “Ameno”.
Advanced Research Projects Agency for Health (ARPA-H)has a program named Sprint for Women’s Health that selects and provides dedicated funding to companies and startups that are working towards the improvement of women’s health. These funds are used towards transformative innovations in the healthcare domain for women and tackle unique and critical healthcare conditions.
Dina Radenkovic is the cofounder and CEO of Gameto, and she is a physician-turned entrepreneur, and she is trying to use science and innovation for lasting positive impact on the lives of women across the globe. She said that this funding will be used to advance the Ameno program by investing in pre-clinical studies and, hopefully, then into the human trials, which will lead to the success of the company and achieve its goal.
At Gameto, there is another program named Fertilo through which the company is trying to address the issue of infertility by reducing the impact of hormonal burden. With this, the company will have the necessary funding for its cell engineering technology that will help in the medical conditions of women going through menopause.
Swastik Saraf is the Founder and Managing Editor of TheMedSector. With a background in data journalism and healthcare research, he specializes in aggregating public health metrics, analyzing institutional data, and mapping out regional healthcare infrastructure. Swastik leads the data compilation team at TheMedSector, ensuring all directory tracking is built on verified primary sources before undergoing formal clinical review.
